Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia

Journal of Clinical Investigation

Volumn 124, Issue 4, 2014, Pages 1587-1597

  Carpenter, Thomas O ^a   Imel, Erik A ^b   Ruppe, Mary D ^c   Weber, Thomas J ^d   Klausner, Mark A ^e   Wooddell, Margaret M ^e   Kawakami, Tetsuyoshi ^e   Ito, Takahiro ^e   Zhang, Xiaoping ^e   Humphrey, Jeffrey ^e   Insogna, Karl L ^a   Peacock, Munro ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; ANTIBODY; CALCITRIOL; CALCIUM; CREATININE; KRN 23 ANTIBODY; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PHOSPHORUS; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AMYLASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIZZINESS; DRUG BIOAVAILABILITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; ELEVATED BLOOD PRESSURE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; IMMUNOGENICITY; KIDNEY CALCIFICATION; MALE; MAXIMUM PLASMA CONCENTRATION; MUTATION; NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; X LINKED HYPOPHOSPHATEMIC RICKETS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CALCIUM; FAMILIAL HYPOPHOSPHATEMIC RICKETS; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KIDNEY TUBULES; MALE; MIDDLE AGED; PHOSPHATES; VITAMIN D; YOUNG ADULT;

EID: 84897560527     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI72829     Document Type: Article

References (20)

1. Imel EA, Econs MJ. Fibroblast growth factor 23: roles in health and disease. J Am Soc Nephrol. 2005;16(9):2565-2575.
2. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol. 2007;18(6):1637-1647. (Pubitemid 46870300)
3. Gattineni J, et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol. 2009;297:F282-F291.
4. Larsson T, et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the α1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology. 2004;145(7):3087-3094. (Pubitemid 38829975)
5. Shimada T, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun . 2004;314(2):409-414. (Pubitemid 38084732)
6. Tenenhouse HS, Econs NJ. Mendelian hypophosphatemia. In: Valle D, et al., eds. The Online Metabolic and Molecular Bases of Inherited Disease. Part 21, Chapter 197. http://ommbid.mhmedical.com/book.aspx?bookID=474#45374201. OMMBID Web site. Accessed January 22, 2014.
7. Reid IR, Hardy DC, Murphy WA, Teitelbaum SL, Bergfeld MA, Whyte MP. X?linked hypophosphapercentage temia: a clinical, biochemical, and histopathologic assessment of morbidity in adults. Medicine (Baltimore). 1989;68(6):336-352. (Pubitemid 19286654)
8. Costa T, et al. X-linked hypophosphatemia: effect of calcitriol on renal handling of phosphate, serum phosphate, and bone mineralization. J Clin Endocrinol Metab. 1981;52(3):463-472. (Pubitemid 11136557)
9. Carpenter T, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician's guide to X?linked hypophosphatemia. J Bone Miner Res. 2011;26(7):1381-1388.
10. Yamazaki Y, et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res. 2008;23(9):1509-1518.
11. Aono Y, et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res. 2009;24(11):1879-1888.
12. Mayo Medical Laboratories. 2013 Online Test Catalog. Test ID: CACRU - Calcium/Creatinine Ratio, Random Urine. Mayo Clinic Web site. http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/ 89604. Accessed January 22, 2014.
13. Aono Y, et al. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice. J Bone Miner Res. 2011;26(4):803-810.
14. Moltz KC, Friedman AH, Nehgme RA, Kleinman CS, Carpenter TO. Ectopic cardiac calcification associated with hyperparathyroidism in a boy with hypophosphatemic rickets. Curr Opin Pediatr . 2001;13(4):373-375. (Pubitemid 32701869)
15. National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events V3.0 (CTCAE). FEMH Web site. http://depart.femh.org.tw/hema/html/CTCAE/ CTCAE%20V3.pdf. Accessed January 22, 2014.
16. Walton RJ, Bijvoet OLM. Nomogram for derivation of renal threshold phosphate concentration. Lancet. 1975;2(7929):309-310.
17. Gibaldi M, Perrier D. Non-compartmental analysis based on statistical moment theory. In: Pharmacokinetics (Drugs and the Pharmaceutical Sciences) . 2nd ed. New York, New York, USA: Marcel Decker Inc.; 1982:409-417.
18. Kratz A. Appendix: Laboratory values of clinical importance. In: Longo DL, Fauci AS, Kasper DL, eds. Harrison's Principles of Internal Medicine . 18th ed. New York, New York, USA: McGraw Hill; 2012:3590-3602.
19. Investigator Laboratory Instruction Manual. Esoterix Clinical Trials Services. http://www.iristrial.org/teleforms/documents/LabCorp%20Manual%20v.8. pdf. Accessed January 22, 2014.
20. Yamazaki Y, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 2002;87(11):4957-4960. (Pubitemid 35316332)